Eugenia Girda

1.9k total citations · 1 hit paper
55 papers, 769 citations indexed

About

Eugenia Girda is a scholar working on Oncology, Reproductive Medicine and Obstetrics and Gynecology. According to data from OpenAlex, Eugenia Girda has authored 55 papers receiving a total of 769 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 16 papers in Reproductive Medicine and 13 papers in Obstetrics and Gynecology. Recurrent topics in Eugenia Girda's work include Cancer Immunotherapy and Biomarkers (15 papers), Ovarian cancer diagnosis and treatment (15 papers) and Endometrial and Cervical Cancer Treatments (12 papers). Eugenia Girda is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Ovarian cancer diagnosis and treatment (15 papers) and Endometrial and Cervical Cancer Treatments (12 papers). Eugenia Girda collaborates with scholars based in United States, Canada and Spain. Eugenia Girda's co-authors include Gary S. Leiserowitz, Gary L. Goldberg, Eric C. Huang, Lloyd H. Smith, Salma K. Jabbour, Kristen Spencer, Roman Groisberg, Nicole Nevadunsky, Anne Van Arsdale and Nancy Chan and has published in prestigious journals such as Journal of Clinical Oncology, Analytical Chemistry and Small.

In The Last Decade

Eugenia Girda

49 papers receiving 761 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

2021 196 citations Matteo Palmeri, Janice M. Mehnert et al. ESMO Open profile →

Peers

Countries citing papers authored by Eugenia Girda

Since Specialization

Citations

This map shows the geographic impact of Eugenia Girda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eugenia Girda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eugenia Girda more than expected).

Fields of papers citing papers by Eugenia Girda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eugenia Girda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eugenia Girda. The network helps show where Eugenia Girda may publish in the future.

Co-authorship network of co-authors of Eugenia Girda

This figure shows the co-authorship network connecting the top 25 collaborators of Eugenia Girda. A scholar is included among the top collaborators of Eugenia Girda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eugenia Girda. Eugenia Girda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A randomized, double-blind, phase II study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib versus pembrolizumab plus lenvatinib among patients with previously-treated mismatch repair proficient advanced endometrial cancer 2024 ·Gynecologic Oncology ·Eugenia Girda, Vicky Makker, Christian Marth, Toon Van Gorp, Mansoor Raza Mirza, (unknown), (unknown), Roman Groisberg, Fan Jin, David M. O’Malley	1
2	1017P Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC) 2024 ·Annals of Oncology ·(unknown), Lin Shen, (unknown), Farshid Dayyani, Jeremy D. Kratz, Hongming Pan, Xiao Liang, Zhishan Wang, Soojin Kim, Ying Deng, Tao Deng, Tao Liu, Eugenia Girda, Chang Xu, Minh Tho Nguyen, Jun Xia, Xiaogang Wang, Sangmi Lee, Jihyoun Jeon, Geoffrey Y. Ku	3
3	Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study 2024 ·Gynecologic Oncology ·Antonio González-Martı́n, Hyun Cheol Chung, Esma Saâda-Bouzid, Eduardo Yáñez, Hélène Senellart, Philippe A. Cassier, Bristi Basu, Bradley R. Corr, Eugenia Girda, Corina E. Dutcus, Chinyere E. Okpara, Razi Ghori, Fan Jin, Roman Groisberg, Zarnie Lwin	8
4	A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results. 2024 ·Journal of Clinical Oncology ·Neil H. Segal, Eugenia Girda, Davendra Sohal, Nehal J. Lakhani, Anthony J. Olszanski, Lawrence Fong, Michael D. Kinnaman, Hyunsil Han, Dimitris Skokos, Kerry A. Casey, (unknown), Bei Wang, Yi Hao, Siyu Li, Samit Ganguly, Israel Lowy, Frank Seebach, Melissa Mathias, Melissa L. Johnson	5
5	Publication rates of podium presentations at the Society of Gynecologic Oncology (SGO) annual meetings 2023 ·International Journal of Gynecological Cancer ·(unknown), Samira Moughrabi, Danielle Glassman, (unknown), Eric A. Singer, Eugenia Girda	1
6	A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update. 2023 ·Journal of Clinical Oncology ·Neil H. Segal, (unknown), Eugenia Girda, Lawrence Fong, Anthony J. Olszanski, Hyunsil Han, Kerry A. Casey, Siyu Li, Erik S. Welf, Chieh-I Chen, Dimitris Skokos, Frank Seebach, Israel Lowy, Matthew G. Fury, Melissa Mathias, Nehal J. Lakhani	5
7	Cervical cancer treatment update: A Society of Gynecologic Oncology clinical practice statement 2023 ·Gynecologic Oncology ·Eugenia Girda, Leslie M. Randall, Fumiko Chino, Bradley J. Monk, John Farley, Roisin E. O’Cearbhaill	10
8	A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers 2023 ·International Journal of Gynecological Cancer ·(unknown), Michael Milosevic, Bradley R. Corr, James L. Abbruzzese, Eugenia Girda, Rachel W. Miller, Jennifer Croke, Helen Mackay, Yeh Chen Lee, Valerie Bowering, (unknown), Lisa Wang, (unknown), Charles A. Kunos, Amit M. Oza, (unknown)	7
9	Disparities in brachytherapy utilization in cervical cancer in the United States: A comprehensive literature review 2023 ·Gynecologic Oncology ·Ritesh Kumar, (unknown), Melissa Lopez, Irina Vergalasova, Xinxin Zhang, (unknown), (unknown), Eugenia Girda, Lara Hathout	7
10	Challenges in treatment of gestational trophoblastic neoplasia in patients with MTHFR mutation: A case report 2023 ·Gynecologic Oncology Reports ·(unknown), Danielle Glassman, (unknown), Eugenia Girda	0
11	LBA43 Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial 2023 ·Annals of Oncology ·Ramez N. Eskander, Michael W. Sill, Austin Miller, (unknown), Richard G. Moore, (unknown), Fernanda Musa, Robert S. Mannel, Mark S. Shahin, (unknown), Eugenia Girda, Cara Mathews, Juraj Kavecansky, Charles A. Leath, Lilian T. Gien, (unknown), Shashikant Lele, Matthew A. Powell, Carol Aghajanian	14
12	Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer 2022 ·International Journal of Gynecological Cancer ·Eugenia Girda, June Y. Hou, David L. Nelson, (unknown), Alexandre Buckley de Meritens, (unknown), Aliza Leiser, (unknown), (unknown), Nancy Chan, Ana I. Tergas, (unknown), Jason D. Wright, Hua Yu, Antons Martincuks, (unknown), Joycelynne Palmer, Lorna Rodrı́guez-Rodrı́guez	8
13	A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors 2022 ·European journal of medical research ·Ann W. Silk, Biren Saraiya, Roman Groisberg, Nancy Chan, Kristen Spencer, Eugenia Girda, Weichung Shih, Marisa Palmeri, Tracie Saunders, Robert Berman, Vlad Coric, Suzie Chen, Andrew Zloza, Joshua A Vieth, Janice M. Mehnert, Jyoti Malhotra	13
14	HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy 2022 ·Gynecologic Oncology ·(unknown), Sharon Wu, (unknown), Nathaniel Jones, Matthew A. Powell, (unknown), Eugenia Girda, Jubilee Brown, (unknown), Rouba Ali‐Fehmi, Ira Winer, Thomas J. Herzog, W. Michael Korn, Britt Erickson	14
15	Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study 2022 ·Gynecologic Oncology ·Ronnie Shapira‐Frommer, Linda Mileshkin, L. V. Manzyuk, Nicolas Penel, Matthew Burge, Sarina A. Piha‐Paul, Eugenia Girda, José A. López-Martín, Marloes G. J. van Dongen, Antoîne Italiano, Lei Xu, Fan Jin, Kevin Norwood, Patrick A. Ott	36
16	Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers breakdown → 2021 ·ESMO Open ·Matteo Palmeri, Janice M. Mehnert, Ann W. Silk, Salma K. Jabbour, Shridar Ganesan, (unknown), Gregory Riedlinger, Ryan D. Stephenson, Alexandre Buckley de Meritens, Aliza Leiser, Tina Mayer, Nancy Chan, Kristen Spencer, Eugenia Girda, Jyoti Malhotra, Timothy A. Chan, Vivek Subbiah, Roman Groisberg	196
17	The Use of Endometrial Cancer Patient-Derived Organoid Culture for Drug Sensitivity Testing Is Feasible 2017 ·International Journal of Gynecological Cancer ·Eugenia Girda, Gary S. Leiserowitz, Lloyd H. Smith, Eric C. Huang	57
18	Two lives, one REBOA 2017 ·The Journal of Trauma: Injury, Infection, and Critical Care ·Rachel M. Russo, Eugenia Girda, (unknown), Misty D. Humphries	17
19	Obesity and Age at Diagnosis of Endometrial Cancer 2014 ·Obstetrics and Gynecology ·Nicole Nevadunsky, Anne Van Arsdale, Howard D. Strickler, Alyson B. Moadel, Gurpreet Kaur, (unknown), Eugenia Girda, Mendel Goldfinger, Gary L. Goldberg, Mark H. Einstein	79
20	Actinomycosis pelvic abscess after in vitro fertilization 2013 ·Fertility and Sterility ·(unknown), Eugenia Girda, (unknown), Genevieve Neal‐Perry, Staci E. Pollack	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact